Tranexamic Acid (TXA)

Tranexamic Acid

The CRASH-2 2 (Clinical Randomisation of an Anti-fibrinolytic in Significant Haemorrhage 2) study involved the randomisation of over 20,000 patients with, or at risk of significant haemorrhage in 40 countries. The study demonstrated a 32% reduction in death due to haemorrhage, when tranexamic acid is administered within 1 h of injury. The study concluded that tranexamic acid safely reduced the risk of death in bleeding trauma patients, and should be considered for use in practice.

Following the publication of the study, the Trust has been working with Professor Stuart Logan, Director of the Peninsula National Institute of Health Research's Collaboration for Leadership in Applied Health Research and Care to implement the intervention across the South West.

For further information please contact Adrian South, Deputy Director of Clinical Care at

Local Resources

Published Evidence

TXA image

Email this page Print page


Marking half a century of service for dedicated clinician
Norman Price, a clinician working for South Western Ambulance Service NHS Foundation Trust (SWASFT), has devoted his entire working life to the ambulance service, and will be the guest of honour at a celebratory event being held between 1500 and 1700 this Thursday, 8 September, at Almondsbury ambulance station, where he is currently based. Reporters and/or photographers are welcome to attend, but will need to confirm in advance.

Rounded corners
Rounded corners
© South Western Ambulance Service NHS Foundation Trust 2016 Design by Precedent | Powered by Sitekit